Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) Shareholder Lawsuit

Our law firm is investigating potential claims on behalf of shareholders of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) over possible violations of US securities laws due to possible false and misleading statements made by the company and its officers. 

If you have purchased shares of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) , call 1-800-934-2921 right now to protect your rights.

 

Our law firm believes that Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) may have violated US securities laws, and the actions of the company may have caused investors of the company to be negatively affected. Specifically, we are investigating whether the companies actions in marketing their drug Juxtapid violate US securities laws. The company received an FDA Warning Letter based on comments CEO Marc Beer made about Juxtapid on CNBC’s “Fast Money." The FDA letter stated that Beer’s public statements indicated that Juxtapid was intended for new uses, for which it lacked FDA approval. The company has also received a subpoena related to the marketing of Juxtapid from the US DOJ. 

Our law firm is investigating potential claims on behalf of shareholders Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) over possible violations of US securities laws due to possible breaches of fiduciary duty by officers of the company. If you have purchased shares of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), contact our law firm right now to protect your rights.

Own shares of  Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR)? Contact us to protect your rights.

If you have purchased shares of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), complete the form on this page or call attorney Bill Kyros at 1-800-934-2921 right now to protect your rights. 

Complete the form below for a free no obligation consultation. 

 

Need assistance with this form?